Genomic profiling of human tumors: moving from cytogenetics to DNA arrays

被引:0
|
作者
Theillet, C
Orsetti, B
Redon, R
du Manoir, S
机构
[1] CRLC, Ctr Rech, CNRS, UMR 5535, F-34298 Montpellier 5, France
[2] ULP, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, F-67404 Illkirch, France
关键词
genome; hybridization;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Genetic instability results, in a large majority of solid tumors, in deep chromosomal rearrangements. However, because chromosomal instability produces highly complex caryotypes, rarely showing stereotypic aberrations, it has not been possible to characterize solid cancers according to specific patterns of chromosomal rearrangements. This contracts with the situation in hematological malignancies, where cytogenetics has allowed to lay out the basis of a renewed classification. New insights have been brought by the development of comparative genomic hybridization (CGH). This molecular cytogenetics approach was originally devised to detect regions in the genome of tumor cells undergoing quantitative changes, i.e. gains or losses of copy numbers. The large body of studies based on CGH show that solid tumors undergo frequent gains and losses and that every chromosomes shaw at least one region of anomaly. Furthermore, different tumor types present distinct CGH patterns of gains and losses. These observations favor the idea that it may be possible to type human solid cancers according to their patterns of genomic aberrations. However; despite the fact that a number of CGH based studies present data suggesting that different tumor types or cancers at different stages of evolution show distinct patterns of gains and losses, it has proven difficult to be conclusive. This can be mainly attributed to the lack of spatial resolution of CGH. indeed CGH uses metaphase chromosomes as hybridization targets and therefore its resolution is at the level of chromosomal banding. The recent adaptation of DNA array technology to CGH will allow to pass this limitation. In DNA array based CGH (array-CGH) metaphase chromosomes have been replaced by spots of cloned DNA. These DNA clones may either be genomic (BACs, YACs or cosmids) or coding (cDNAs). The resolution of array-CGH is therefore determined by the size of the cloned DNA insert (100 Kb for BACs, 1-2 kb for cDNAs). Data corresponding to each of these clones is or will be in a near future linked to DNA sequence data. Hence, in a near future, array-CGH will allow to increase the resolution from a cytogenetic level to a molecular level. Finally, because array technology is highly adaptable to automation, going am classical CGH to array-CGH will produce a quantum leap in throughput.
引用
收藏
页码:261 / 268
页数:8
相关论文
共 50 条
  • [41] Genomic Profiling of Primary and Metastatic Malignant Phyllodes Tumors
    Yildirim, Selma Yeni
    Selenica, Pier
    Gazzo, Andrea
    Ross, Dara
    Brogi, Edi
    Weigelt, Britta
    Pareja, Fresia
    LABORATORY INVESTIGATION, 2025, 105 (03)
  • [42] From Human Cytogenetics to Human Chromosomics
    Liehr, Thomas
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (04):
  • [43] A demonstration of genomic DNA profiling by RAPD analysis
    Hammond, JBW
    Spanswick, GS
    BIOCHEMICAL EDUCATION, 1997, 25 (02): : 109 - 111
  • [44] Comparative genomic hybridization using oligonucleotide arrays and total genomic DNA
    Barrett, MT
    Sampas, N
    Ben-Dor, A
    Scheffer, A
    Anderson, P
    Tsang, P
    Gooden, C
    Walker, R
    Curry, B
    Kincaid, R
    Lipson, D
    Bittner, M
    Yakhini, Z
    Meltzer, PS
    Bruhn, L
    Laderman, S
    BREAST CANCER RESEARCH, 2005, 7 (Suppl 2) : S51 - S51
  • [45] Comparative genomic hybridization using oligonucleotide arrays and total genomic DNA
    MT Barrett
    N Sampas
    A Ben-Dor
    A Scheffer
    P Anderson
    P Tsang
    C Gooden
    R Walker
    B Curry
    R Kincaid
    D Lipson
    M Bittner
    Z Yakhini
    PS Meltzer
    L Bruhn
    S Laderman
    Breast Cancer Research, 7
  • [46] Genomic Profiling of Circulating Tumor DNA From Cerebrospinal Fluid to Guide Clinical Decision Making for Patients With Primary and Metastatic Brain Tumors
    Ramkissoon, Lori A.
    Pegram, Worthy
    Haberberger, James
    Danziger, Natalie
    Lesser, Glenn
    Strowd, Roy
    Dahiya, Sonika
    Cummings, Thomas J.
    Bi, Wenya Linda
    Abedalthagafi, Malak
    Sathyan, Pratheesh
    McGregor, Kimberly
    Reddy, Prasanth
    Severson, Eric
    Williams, Erik
    Lin, Douglas
    Edgerly, Claire
    Huang, Richard S. P.
    Hemmerich, Amanda
    Creeden, James
    Brown, Charlotte
    Venstrom, Jeffrey
    Hegde, Priti
    Ross, Jeffrey S.
    Alexander, Brian M.
    Elvin, Julia
    Ramkissoon, Shakti H.
    FRONTIERS IN NEUROLOGY, 2020, 11
  • [47] Biological, Diagnostic, and Therapeutic Insights from (Epi)Genomic Profiling of Pediatric Brain Tumors
    De Cola, Antonella
    Foss, Amelia
    Gilbertson, Richard
    Pathania, Manav
    ANNUAL REVIEW OF CANCER BIOLOGY, 2024, 8 : 199 - 226
  • [48] Neuroblastoma: from molecular cytogenetics to gene expression profiling
    Vandesompele, J
    Van Roy, N
    Berx, G
    Plantaz, D
    De Paepe, A
    Laureys, G
    van Roy, F
    Speleman, F
    CYTOGENETICS AND CELL GENETICS, 1999, 85 (1-2): : 25 - 25
  • [49] GENOMIC PROFILING OF CIRCULATING TUMOR DNA FROM PERITONEAL FLUID IN ENDOMETRIAL CANCER
    Choi, Youn Jin
    Han, Mi-Ryung
    Ju, Hye-Yeon
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A90 - A90
  • [50] Analytical validation of comprehensive assays for genomic profiling of cancer from DNA and RNA
    Beck, J.
    Newburn, E.
    Clark, M.
    Lefterova, M.
    Helman, E.
    Alla, R.
    Church, D.
    Boyle, S.
    Luo, S.
    Morra, M.
    Harris, J.
    Leng, N.
    Haudenschild, C.
    Chen, R.
    West, J.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S64 - S65